SOM230: a new therapeutic modality for Cushing's disease.

Lewis, Ian; Schmid, Herbert A; Kneuer, Rainer; Hoyer, Daniel; Silva, Antonio P; Weckbecker, Gisbert; Bruns, Christian; Pless, Janos

Lewis, Ian; Schmid, Herbert A; Kneuer, Rainer; Hoyer, Daniel; Silva, Antonio P; Weckbecker, Gisbert; Bruns, Christian; Pless, Janos.

Afiliación

Lewis I; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland. ian.lewis@novartis.com.
Schmid HA; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Kneuer R; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Hoyer D; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Silva AP; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Weckbecker G; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Bruns C; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.
Pless J; Global Discovery Chemistry Novartis Institutes of Biomedical Research CH-4002 Basel, Switzerland.

Chimia (Aarau) ; 68(7-8): 483-4, 2014.

Article en En | MEDLINE | ID: mdl-25437387

Asunto(s)

Síndrome de Cushing/tratamiento farmacológico; Somatostatina/análogos & derivados; Humanos; Modelos Moleculares; Somatostatina/síntesis química; Somatostatina/química; Somatostatina/uso terapéutico

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Somatostatina / Síndrome de Cushing Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Chimia (Aarau) Año: 2014 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google